BSX
Value In WatchlistBoston Scientific Corp
Company Overview
bostonscientific.comBoston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular. It offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, SpyGlass, single-use scopes used for diagnostic and therapeutic procedures in the pancreaticobiliary syst...em, in endoscopic retrograde cholangiopancreatography procedures, and single-use duodenoscopes, as well as endoluminal surgery and infection prevention products; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, urinary and bowel dysfunction, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, penile implants, artificial urinary sphincter, laser system, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator systems, radiofrequency ablation, and intraosseous nerve ablation and deep brain stimulation systems. The company also provides technologies for diagnosing and treating a range of diseases and abnormalities of the heart; WATCHMAN FLX, a left atrial appendage closure (LAAC) device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, it offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose and treat forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
Fundamental Snapshot
Company Info
Valuation
Profitability
Risk / Health
Interpretation:
8-9: Very Strong
5-7: Stable
0-4: Weak (Risk)
Interpretation:
> 3.0: Safe Zone
1.8 - 3.0: Grey Zone
< 1.8: Distress Zone (High Risk)
Interpretation:
< -1.78: Unlikely Manipulator
> -1.78: Possible Manipulator
Price (1Y)
Revenue Growth (YoY)
15.9%
Revenue CAGR (3Y)
17.7%
Revenue CAGR (5Y)
14.3%
Earnings CAGR (3Y)
68.4%
FCF CAGR (3Y)
33.3%
FCF CAGR (5Y)
14.0%
Industry Benchmark: Healthcare Products
204 firms | Source: DamodaranPE (Current)
55.9x
PE (Forward)
42.3x
P/S
4.36x
EV/EBITDA
19.8x
ROE
11.3%
Net Margin
9.6%
Income & Cash Flow
Revenue ($B)
Gross Profit ($B)
Operating Income ($B)
Net Income ($B)
Free Cash Flow ($B)
Op. Cash Flow ($B)
Expenses
Cost of Revenue ($B)
Operating Expenses ($B)
R&D Expense ($B)
SG&A Expense ($B)
Cash & Debt
Cash & Equivalents ($B)
Total Debt ($B)
Net Debt ($B)
Shareholders' Equity ($B)
Shares, Dividends & Valuation
Shares Outstanding (B)
Dividends Paid ($B)
P/E Ratio
P/S Ratio
EV/EBITDA
Price vs FCF Fair Value
Avg: 25.1xPrice vs OCF Fair Value
Avg: 31.7xPrice vs Earnings Fair Value
Avg: 58.8xPrice vs EBIT Fair Value
Avg: 37.9xPrice vs EBITDA Fair Value
Avg: 26.5xPrice vs Sales Fair Value
Avg: 5.5xSegment KPIs
Coming soon - custom metrics from company filings